AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.

The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

The Investment Committee give you their top stocks to watch for the second half. Maggie Smith, acting legend of 'Harry Potter ...

AbbVie on Friday said the application covers telisotuzumab vedotin, or teliso-V, in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor wild type, ...

AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in ...

AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease.

AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA ...